APLT241220P7500
- 6.34
- +0.04+0.63%
Applied Therapeutics Newsroom
Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx
Express News | Applied Therapeutics Inc - Joel Marcus Resigns From Applied Therapeutics Board
Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors
(APLT) - Analyzing Applied Therapeutics's Short Interest
William Blair Maintains Applied Therapeutics(APLT.US) With Buy Rating
Buy Rating Maintained for Applied Therapeutics Amidst SORD Program Potential and Regulatory Challenges
Insiders Could Have Profited By Holding Onto Applied Therapeutics Shares Despite 84% Drop
Optimistic Outlook for Applied Therapeutics Despite FDA Setback
Applied Therapeutics Faces FDA Challenges With Govorestat
Express News | Applied Therapeutics: Following Issuance of a Complete Response Letter by FDA, Received Warning Letter Limited to at-007-1002 Study
Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says
Netflix To Rally More Than 7%? Here Are 10 Top Analyst Forecasts For Monday
Express News | Applied Therapeutics Inc : UBS Cuts Target Price to $2 From $13
Express News | Applied Therapeutics Inc : UBS Cuts to Neutral From Buy
Applied Therapeutics Price Target Lowered to $5 From $14 at Baird
Applied Therapeutics CRL a 'Major Setback,' Says William Blair
Applied Therapeutics Downgraded to Sector Perform From Outperform at RBC
Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow
Applied Therapeutics Price Target Cut to $8.00/Share From $13.00 by Citigroup
Applied Therapeutics Is Maintained at Buy by Citigroup